: The use of antimicrobials to treat food animals leaves antimicrobial residues in foodstuffs. The World Health Organization (WHO) defines the acceptable daily intakes (ADIs) of these residues as the dose of these antimicrobials that is safe for an average human to consume on a daily basis. We hypothesized that the lowest dose of ciprofloxacin classified as safe by the WHO could select for ciprofloxacin-resistant strains of in a model. : We aimed to evaluate if the consumption of peri-ADI doses of ciprofloxacin could select for ciprofloxacin-resistant (Ser464Phe, GyrB, ciprofloxacin MIC of 4 µg/mL) compared to -susceptible (isogenic, ciprofloxacin MIC of 0.047 µg/mL) strains of in a model. : A significant increase was seen in the proportion of resistance for the 1× ADI and 1/10th ADI concentrations on day 2 compared to the positive control. : A model of infection in larvae was used for the experiment. The larvae were inoculated with followed by 10× ADI, 1× ADI, 1/10th ADI, 1/100th ADI, and 1/1000th ADI doses of ciprofloxacin. The isolation of colonies was then performed on selective agar plates with and without ciprofloxacin (1 µg/mL). The proportion of colonies with ciprofloxacin resistance was then calculated for each group at 24 and 48 h. : We found that, at 48 h, there was an enrichment of colonies with ciprofloxacin resistance in the larvae receiving 1× ADI and 1/10th ADI concentrations of ciprofloxacin. These results suggest that the ciprofloxacin MSC for in this model is 1/10th of the acceptable daily concentration (ADI) dose of ciprofloxacin, which is equivalent to 0.239 ng/µL.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11591287PMC
http://dx.doi.org/10.3390/antibiotics13111097DOI Listing

Publication Analysis

Top Keywords

ciprofloxacin
12
1× adi
12
adi 1/10th
12
1/10th adi
12
adi
10
acceptable daily
8
dose ciprofloxacin
8
select ciprofloxacin-resistant
8
strains model
8
doses ciprofloxacin
8

Similar Publications

Objectives: Urinary tract infections (UTIs) are an important cause of empiric antibiotic (over)treatment at the emergency department (ED). To enhance empiric antibiotic choices, mapping the national and local microbiology and antimicrobial resistance (AMR) patterns is crucial. This study aims to examine resistance patterns at a Brussels ED and to identify risk factors for AMR to evaluate current treatment guidelines and help combat AMR.

View Article and Find Full Text PDF

The adsorption and aggregation of amphiphiles at different solvent interfaces are of great scientific and technological importance. In this study, interfacial tension measurements of surface-active compounds-ionic liquid 2-dodecyl-2,2dimethylethanolammonium bromide (12Cho.Br) and cationic surfactant cetyltrimethylammonium bromide (CTAB)-were conducted both in the absence and presence of ciprofloxacin (CIP).

View Article and Find Full Text PDF

A 39-year-old woman presented to the dermatology department in January 2022 with a 3-week history of a progressively enlarging and intensely pruritic erythematous annular nodule on her left hand. The lesion started as a small blister, which was initially presumed to be a flare up of her pompholyx dermatitis. On her physician's advice, she applied clobetasol propionate ointment twice daily for 5 days; however the blister continued to increase in size until it burst, revealing raw inflamed skin.

View Article and Find Full Text PDF

Antimicrobial resistance poses a global public health threat, compelling the search for alternative treatments, especially in resource-limited settings. The increasing ineffectiveness of traditional antibiotics has intensified the need to explore medicinal plants as viable therapeutic options. This study sought to compare the efficacy of certain medicinal plants used in Owerri, Nigeria, for treating pathogenic bacteria against traditional commercial antibiotics.

View Article and Find Full Text PDF

Rifampicin and isoniazid resistance not promote fluoroquinolone resistance in Mycobacterium smegmatis.

PLoS One

January 2025

National Clinical Research Center for Infectious Diseases, Shenzhen Clinical Research Center for Tuberculosis, Shenzhen Third People's Hospital, Shenzhen, Guangdong, China.

Background: The emergence of drug-resistant Tuberculosis (TB) has made treatment challenging. Although fluoroquinolones (FQs) are used as key drugs in the treatment of multidrug-resistant tuberculosis (MDR-TB), the problem of FQs resistance is becoming increasingly serious. Rifampicin (RIF) resistance is considered a risk factor for FQs resistance.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!